Beckman Coulter, Seegene Ink MDx Supply Agreement | GenomeWeb

NEW YORK (GenomeWeb) — Beckman Coulter and Seegene yesterday announced after the close the market an agreement under which Seegene will manufacture reagents designed exclusively for Beckman Coulter's new Veris MDx sample-to-answer molecular diagnostics system.

Specifically, Beckman Coulter will incorporate Seegene's dual-priming oligonucleotide (DPO), tagging oligonucleotide capture and extension (TOCE), and MuDT assay chemistries into its MDx platform, Beckman Coulter CSO Richard Creager said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.